A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Completed · Phase 1

Conditions studied: Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome

In brief

This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and tolerability of SB939 in combination with standard azacitidine therapy.

Key facts

Study ID
NCT00741234
Run by
S*BIO
People needed
85
Starts
2007-04-01
Expected to finish
2012-03-01
Last updated by the study team
2012-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.